About STAT Diagnostica
STAT Diagnostica is a Healthcare company based in Barcelona (Spain) founded in 2010. Diagnostic platform for molecular diagnostics and immunoassays is provided. STAT Diagnostica has raised $53.66 million across 4 funding rounds from investors including Idinvest Partners, Kurma Partners and Official Credit Institute. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics.
Company details
Provider of a diagnostic platform for molecular diagnostics and immunoassays. The proprietary DiagCore comprises an Analyzer that runs on consumable DiagCore cartridges. The STAT-Molecular cartridge automates sample homogenization, cell disruption, nucleic acid purification and delivers up to 50-plex target detection employing qPCR. This test cartridge is designed to automate molecular assays in the fields of infectious diseases, oncology, coagulation, prenatal, inherited diseases, or companion diagnostics. It offers test cartridges designed to automate immunoassays for critical care markers such as Procalcitonin (Sepsis), Troponin (AMI), Ngal (AKI), C-reactive protein (Inflammation), hCG (pregnancy), among others.
- Headquarters Barcelona, Spain
- SectorsHealthcare
- Website stat-diagnostica.com
- Total Equity Funding$53.66M (USD)
in 4 rounds
- InvestorsIdinvest Partners
& 8 more
Funding Insights of STAT Diagnostica
STAT Diagnostica has successfully raised a total of $53.66M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $53.66M
- Total Rounds 4
- First Round $2.89M
(Jun 2011)
- Investors Count 9
All 4 funding rounds of STAT Diagnostica with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2016 | Series C | – | Next47 | – | |
| Apr 2016 | $28.48M | Series C | – | Gilde Healthcare | |
| May 2013 | $22.29M | Series B | – | Kurma Partners | |
| Jun 2011 | $2.89M | Series A | – | Ysios Capital |
9 investors in total: 9 institutional.
Investors in STAT Diagnostica
STAT Diagnostica has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Idinvest Partners, Kurma Partners and Official Credit Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture investments in systems, infrastructure, and applications for enterprise founders. | next47.com | |||
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
Biotech startups are funded through venture capital in life sciences. | 2009 | kurmapartners.com | Paris, France | |
Ysios Capital is recognized as a leading life sciences investor. | ysioscapital.com | Barcelona, Spain | ||
Equity investments are provided to low and middle market companies. | 1997 | idinvest.com | Paris, France | |
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund. | boehringer-ingelheim-venture.com | |||
Venture capital investments are focused on healthcare and multiple sectors. | caixacapitalrisc.es | Barcelona, Spain | ||
ICO Axispart is engaged in providing financial solutions for businesses. | 1971 | axispart.com | Madrid, Spain | |
Provider of SME loans | 1993 | ico.es | Madrid, Spain |
Investor details for STAT Diagnostica
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of STAT Diagnostica
3 dated milestones of STAT Diagnostica across 6 years, from founding to its latest funding, stage changes and deals.
- Founded STAT Diagnostica is founded.
- Funding First funding round of $2.9M.
- Funding Latest funding round, Series C,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about STAT Diagnostica
STAT Diagnostica was founded in 2010 and raised its 1st funding round 1 year after it was founded.
STAT Diagnostica is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
STAT Diagnostica is a funded company, having raised a total of $53.66M across 4 funding rounds to date. The company's 1st funding round was a Series A of $2.89M, raised on Jun 2011.
Provider of a diagnostic platform for molecular diagnostics and immunoassays. The proprietary DiagCore comprises an Analyzer that runs on consumable DiagCore cartridges. The STAT-Molecular cartridge automates sample homogenization, cell disruption, nucleic acid purification and delivers up to 50-plex target detection employing qPCR. This test cartridge is designed to automate molecular assays in the fields of infectious diseases, oncology, coagulation, prenatal, inherited diseases, or companion diagnostics. It offers test cartridges designed to automate immunoassays for critical care markers such as Procalcitonin (Sepsis), Troponin (AMI), Ngal (AKI), C-reactive protein (Inflammation), hCG (pregnancy), among others.
STAT Diagnostica has 9 investors. Key investors include Idinvest Partners, Kurma Partners, Official Credit Institute, Next47, and Gilde Healthcare.